Chronic myelogenous leukemia (CML) is a clonal disorder of the hematopoietic stem cell characterized by a chimeric BCR/ABL gene giving rise to a 210-kD fusion protein with dysregulated tyrosine kinase activity. We investigated the effect of genistein, a protein tyrosine kinase inhibitor, on the in vitro growth of CML and normal marrow-derived multipotent (colony-forming unit-mix [CFU-Mix]), erythroid (burst-forming unit-erythroid [BFU-El), and granulocytemacrophage (colony-forming unit-granulocyte-macrophage [CFU-GM]) hematopoietic progenitors. Continuous exposure of CML and normal marrow t o genistein induced a statistically significant and dose-dependent suppression of colony formation. Genistein doses causing 50% inhibition of CML and normal progenitors were not significantly different for
Chronic myelogenous leukemia (CML) is a clonal disorder of the hematopoietic stem cell characterized by a chimeric BCR/ABL gene giving rise to a 210-kD fusion protein with dysregulated tyrosine kinase activity. We investigated the effect of genistein, a protein tyrosine kinase inhibitor, on the in vitro growth of CML and normal marrow-derived multipotent (colony-forming unit-mix [CFU-Mix]), erythroid (burst-forming unit-erythroid [BFU-El), and granulocytemacrophage (colony-forming unit-granulocyte-macrophage [CFU-GM]) hematopoietic progenitors. Continuous exposure of CML and normal marrow t o genistein induced a statistically significant and dose-dependent suppression of colony formation. Genistein doses causing 50% inhibition of CML and normal progenitors were not significantly different for CFU-Mix (27 pmol/L W 23 pmol/L), BFU-E (31 pmol/L Y 29 pmol/L), and CFU-GM (40 pmol/L W 32 pmol/L). Preincubation of CML and normal marrow with genistein (200 pmoll L for 1 to 18 hours) induced a time-dependent suppression of progenitor cell growth, while sparing a substantial proportion of long-term culture-initiating cells (LTC-IC) from CML (range, 91% 2 9% to 32% f 3%) and normal marrow (range, 85% f 8% to 38% k 9%). Analysis of individual CML HRONIC MYELOGENOUS leukemia (CML) is a clonal myeloproliferative disorder due to an acquired abnormality in a pluripotential hematopoietic stem cell.' CML is cytogenetically marked by the Philadelphia (Ph) chromosome, which originates from a reciprocal translocation between chromosomes 9 and 22, and is molecularly marked by a chimeric BCWABL gene, resulting from juxtaposition of the ABL proto-oncogene on chromosome 9 with the BCR gene, which is normally located on chromosome 22.* The chimeric BCWABL gene expresses an 8.5-kb hybrid mRNA transcript giving rise to a 210-kD fusion protein (p210BCWABL) with increased tyrosine kinase a~tivity,~ transforming activity for hematopoietic cells," and the ability to cause CML-like myelopoiesis in mice.5 Dysregulated tyrosine kinase activity of the p210BCWABL fusion protein and the subsequent changes in the normal pattern of phoshorylation of regulatory proteins play a key role in the pathogenesis of CML.6.7 Signal transduction substrates directly involved in BCWABL-dependent leukemogenesis include ~2 1 ' "~ and ~1 2 0 G A p .~ The Src homology 2 (SH2) and Src homology 3 (SH3) domain-containing Grb-2 protein links tyrosine kinases to Ras signaling.lO," Binding of Grb-2 to BCWABL is mediated by the direct interaction of the Grb-2 SH2 domain with a phosphorylated tyrosine within the BCR first exon." BCWABL tyrosine kinases also phosphorylate Shc proteins on tyrosine, inducing the formation of an Shc-Grb-2 complex that also has the potential to stimulate Ras.I3 Another important substrate is the SH2/SH3 domain-containing CRKL protein, which is phosphorylated by and also forms specific complexes with p210BCWABL.14 Although recombinant interferon-a can prolong survival of CML patients,I5 the only curative treatment for these patients remains allogeneic bone marrow transplantation, In the past decade, several natural or synthetic compounds able to inhibit the signaling cascades triggered by protein tyrosine kinases (PTKs) have been generated.30 Inhibitors of PTK catalytic activity that exhibit rather broad specificity in the micromolar range include genistein, quercetin, herbimycin A, and tyrph~stins.~' Genistein, a naturally occurring PTK inhibitor, has been shown to exhibit specific inhibitory activity against receptor and cytoplasmic tyrosine kinases, including epidermal growth factor receptor, pp60""", pp1 10gag-fes, platelet-derived growth factor receptor, and cGenistein induces differentiation and apoptosis of HL-60 and K562 cells35 and may also inhibit topoisomerases I and II.36 Using established leukemic cell lines, it has been shown that genistein, herbimycin A, and tyrphostin inhibit p21OBCwABL tyrosine kinase However, the effect of PTK inhibitors on primary CML cells has not been extensively investigated.
C
Therefore, it was the aim of the present study to evaluate the effect of genistein on the in vitro growth of marrowderived CML and normal progenitors grown in methylcellulose in the continuous presence or after a transient exposure to genistein. In addition, the capability of genistein to select in vitro for BCWABL-progenitors was investigated by detecting the BCWABL mRNA on single progenitors by reverse transcription-polymerase chain reaction (RT-PCR).
kit. [32] [33] [34] 
MATERIALS AND METHODS

Patients.
Seven patients with Ph' CML were included in this study ( Table 1) . Three patients (nos. I , 3, and 6) were evaluated at diagnosis and before any treatment; the others had been diagnosed 3 to 55 months before the study and had received prior treatment with hydroxyurea, interferon-a, or mafosfamide-purged ABMT (no. 5). At the time of the study, all patients were in the chronic phase.
Cell separation procedures. After informed consent was obtained, bone marrow was obtained from normal donors or CML patients by aspiration from the posterior iliac crest and mononuclear cells (MNC) were separated by centrifugation (400g for 30 minutes at 4°C) on a Ficoll-Hypaque gradient (density = 1.077 g/mL). Interface cells were washed and suspended in RPMI-1640 (GIBCO, Grand Island, NY) supplemented with 20% fetal bovine serum (FBS; Hyclone, Logan, UT). Monocyte-macrophage cells were removed by adherence to plastic for 60 minutes (37°C and 5% CO2).
Colony-forming unit-mix (CFU-Mix), burst-forming unit-erythroid (BFU-E), and colony-jorming unir-granulocyte-macrophage (CFlJ-GM) assay. The assay for multilineage colony-forming units (CFU-Mix), erythroid bursts (BFU-E), and granulocyte-macrophage colony-forming units (CFU-GM) was performed as described elsewhere. Briefly, 5 X 1 O4 MNC-AC-cells were plated in 35-mm Petri dishes in I-mL aliquots of Iscove's modified Dulbecco's medium (IMDM; Seromed, Berlin, Germany) containing 30% FBS (Stem Cell Technologies, Vancouver, British Columbia, Canada), m o m 2-mercaptoethanol (GIBCO), and 1 .l % (wt/vol) methylcellulose. Cultures were stimulated with interleukin-3 ([L-3; 10 nglmL: Sandoz, Basel, Switzerland), granulocyte colony-stimulating factor (G-CSF; 10 ng1mL; Amgen Inc, Thousand Oaks, CA), granulocytemacrophage colony-stimulating factor (GM-CSF; I O ng/mL; Sandoz), and erythropoietin (3 U/mL; Amgen Inc). Progenitor cell growth was evaluated after incubation (37°C and 5% COn) for 14 to 18 days in a humidified atmosphere. Four dishes were set up for each individual data point per experiment. Colonies were scored according to previously published criteria.
Long-term culture-initiating cell (LTC-IC) assay. The LTC-IC assay was performed according to Sutherland et al ! " Briefly, test cell (3 to 5 X 10' MNC-AC-) suspensions were seeded into cultures containing a feeder layer of irradiated (8,000 cGy) murine M2-10B4 cells (3 X 104/cm2; kindly provided by Dr C. Eaves, Teny Fox Laboratory, Vancouver, British Columbia, Canada) engineered by retroviral gene transfer to produce human IL-3 and human G-CSF.4' Test cells were resuspended in complete medium consisting of amedium (GIBCO) supplemented with FBS (12.5%), horse serum (12.5%), L-glutamine (2 mmo&), 2-mercaptoethanol ( molk), inositol (0.2 mmolk), folic acid (20 pmolk), and freshly dissolved hydrocortisone mom). Cultures were fed weekly by replacement of half of the growth medium containing half of the nonadherent cells with fresh complete medium. After 5 weeks in culture, nonadherent cells and adherent cells harvested by trypsinization were pooled, washed, and assayed together for clonogenic cells in standard methylcellulose cultures at an appropriate concentration (usually 5 X 104/mL). The total number of clonogenic cells (ie, CFU-Mix plus BFU-E plus CFU-GM) present in 5-week-old LTC provides a relative measure of the number of LTC-IC originally present in the test suspension. Absolute LTC-IC values were calculated by dividing the total number of clonogenic cells by 4, which is the average output of clonogenic cells per LTC-IC, according to limiting dilution analysis studies reported by others.
Cytogenetic analysis. Cytogenetic analysis and standard GTGor QFQ-banding techniques were performed according to standard method^.^' To exclude that genistein could induce false-negative results by blocking BCWABL gene expression from otherwise Ph'
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colonies, individual colonies were aspirated, divided into two aliquots, and analyzed both at the cytogenetic and molecular level. Briefly, colcemid (1 pg/rnL; 100 pL/dish) was added to cultures by using a 26-gauge syringe needle 3 to 4 hours before the end of the incubation period. Colonies were individually removed, transferred into a 96-well tissue culture plate containing 40 pL KC1 (0.075 mol/ L), and dispersed by gently pipelting up and down. Half of the cell suspension was then aspirated and processed by RT-FTR for BCW ABL mRNA detection, whereas the remaining cells were processed for cytogenetic analysis according to a previously described technique.
Detection of BCWABL mRNA in individual progenitors. BCW ABL mRNA was detected by RT-PCR. Colonies were individually removed under an inverted microscope using micropipette tips and transferred into microcentrifuge tubes containing 40 pL phosphatebuffered saline (PBS). After adding guanidinium thiocyanate (40 pL), colonies were frozen at -70°C until nested RT-PCR was performed. Total RNA was extracted from thawed colonies according to the method of Chomczynski and Sa~chi:~ with slight modifications. Briefly, 500 pL of TRIzol (GIBCO) and 5 pg of MS2 phage RNA (Boehringer Mannheim, Mannheim, Germany) as a carrier were added to each tube. After incubation for 5 minutes at room temperature, 100 pL of chloroform was added and each tube was vigorously shaken and centrifuged (12,OOOg for 15 minutes at 4°C). Finally, the upper aqueous phase was aspirated and RNA was precipitated with isopropanol, centrifuged (12,000g for IO minutes at 4 T ) , washed with ethanol (75%), dried (room temperature), and redissolved in RNAse-free water (55°C to 60°C for 10 minutes). Total RNA from each colony was reverse transcribed to cDNA in a final volume of 20 pL, using 1.1 nmol of hexa random primer, IO mmoVL dithiothreitol (DTT), 0.125 mmoVL dNTP (GIBCO), 40 U of RNAse Inhibitor (Boehringer Mannheim), and 200 U of murine leukemia virus (MLV) reverse transcriptase (GIBCO) in PCR buffer (50 mmoVL Tris-HCI, 75 mmoVL KCI, and 3 mmoVL MgC12). The mixture was incubated at 37°C for 1 hour and quickly chilled on ice. Total cDNA from each colony was divided into two aliquots for detection of the BCWABL rearrangement and the internal ABL sequence, respectively. The first PCR amplification was performed in a final volume of 45 p L using 10 pL of the reverse transcription mixture, 0.25 mmol/L dNTP, 0.57 pmolR. of each primer, and 2 U of Taq polymerase (GIBCO) in PCR buffer (20 mmoUL Tris-HCI, 50 mmoUL KCI, and 1.5 mmoVL MgCI2). Forty-five cycles, each consisting of 30 seconds at 94°C. 30 seconds at 60°C and 30 seconds at 7 2 T , were performed using a Perkin-Elmer Cetus DNA Thermal Cycler (Perkin-Elmer Cetus, Nonvalk, CT). PCR was performed using the primers of Martiat et aLh2 The BCWABL primer sequences were 5'-GAA GAA GTG TTT CAG AAG CTT CTC CC-3' (sense) and 5'-GAC CCG GAG CTT TTC ACC TIT AGT T-3' (antisense). The ABL primer sequences were 5'-TTC AGC GGC CAG TAG CAT CTG ACT T-3' (sense) and 5'-GAC CCG GAG CTT TTC ACC " F AGT T-3' (antisense). Reamplification of 1 pL of the first PCR product was performed for BCWABL under slightly modified conditions (35 cycles, each consisting of 30 seconds at 94"C, 30 seconds at 55°C and 30 seconds at 72°C) using oligonucleotide primers internal to the original primers. The BCWABL internal nested primer sequences were 5'-GTG AAA CTC CAG ACT GCT CAC AGC A-3' (sense) and 5'-TCC ACT GGC CAC AAA ATC ATC ATA CAGT-3' (antisense). The reaction products were electrophoretically separated through a 2% agarose gel and stained with ethidium bromide. The expected products generated by PCR were, for BCWABL, 272 bp and 197 bp, depending on the position of junction point within M-BCR. The expected product generated by PCR for ABL was 185 bp. Two negative controls consisting of RNA isolated from normal marrow CFU-GM and of sterile diethylpyrocarbonate (DEPC) water (Sigma, St Louis, MO), including all reagents without RNA, were performed in each experiment. As a positive control, RNA extracted from single K562 colonies was used. To ensure that RNA could be reverse transcribed and subsequently amplified, control amplification using exon 2-exon 3 ABL sequencespecific primers was performed in all samples. Only colonies with an internal positive control were considered evaluable. Because ABL was already detectable after the first PCR amplification (on average, 90% of the colonies gave rise to an ABL signal of good quality after a one-step RT-FTR), the first PCR product of ABL was not reamplified. After a one-step PCR, using a 5' primer on ABL exon 2 and a 3' primer on ABL exon 3, amplification of genomic DNA contaminating RNA preparations is expected to give rise to a PCR product with a higher molecular weight as compared with the product generated by cDNA.".~~ However, to exclude that the amplification of genomic DNA, in the absence of cDNA, could produce an ABLpositive signal, each ABL detection was controlled by amplifying a sample that had not reverse transcribed. Such samples failed to show any ABL amplification.
Nuclear DNA fragmentation. Nuclear DNA fragmentation was detected by DNA gel electrophore~is~~ and terminal deoxynucleotidyl transferase (TdT) assay!'
To perform DNA gel electrophoresis, untreated and genistein-treated MNC-AC-or CD34+ cell samples were collected by centrifugation; washed in PBS; resuspended in 20 pL 10 mmol/L EDTA, 50 mmol/L Tris-HCI (pH 8.0) containing 0.5% (wt/vol) sodium lauryl sarkosinate and 0.5 mg/mL proteinase K (Boehringer Mannheim); and incubated at 50°C for 1 hour. After the addition of IO pL RNase A (0.5 mg/mL), incubation at 50°C was continued for 1 hour. Samples were heated to 7 0 T , and IO pL I O mmol/L EDTA (pH 8.0) containing 1% (wtlvol) agarose, 0.25% (wt/vol) bromophenol blue, and 40% (wt/vol) sucrose was mixed with each sample before loading into the dry wells of a 2% (wt/vol) agarose gel containing 0.1 pg/mL ethidium bromide. Electrophoresis was performed in 2 mmol/L EDTA, 800 mmol/L Tris-phosphate (pH 7.8) until the marker dye had migrated 3 to 4 cm. To perform the TdT assay, cells were fixed in PBS containing 4% paraformaldehyde, washed, and permeabilized with 0.1% Triton X-100. After washing, cells were resuspended in 50 pL of a solution containing 0.1 mol/ L sodium cacodylate, 1 mmol/L CoCI,, 0.1 mmoVL dithiothreitol, 0.05 mg/mL bovine serum albumine, IO U of TdT, and 0.5 nmol fluorescein isothiocyanate (FITC)-conjugated biotin-16-deoxyuridine triphosphate. All chemicals and nucleotides were purchased from Boehringer Mannheim. The cells were incubated for 60 minutes at 37°C and analyzed by flow cytometry on a FACSort (Becton Dickinson, Mountain View, CA).
Genistein treatment. Genistein (Sigma) was diluted in dymethylsulfoxide to prepare 1,000-fold concentrated solutions that were used at a final concentration of 0.1% (voVvol) to obtain the appropriate concentrations in culture. The effect of genistein was evaluated by continuous exposure and preincubation experiments. For continuous exposure experiments, MNC-AC-(50,00O/mL) were cultured throughout the entire incubation period in the presence of varying doses of genistein (1 to 100 pmoVL). For each experiment, appropriate controls with vehicle alone (dimethyl sulfoxide [DMSO]; 1 pL/dish) were set up. For preincubation experiments, MNC-AC-(1 X 106/mL) were exposed (1 to 18 hours at 37°C and 5% CO2) to either control medium (IMDM and 10% FBS) or medium containing genistein (50 to 200 prnol/L). At the end of the incubation period, the cells were washed three times and cultured to quantitate CFUMix, BFU-E, CFU-GM, and LTC-IC.
Statistical analysis. Four plates were scored for each data point per experiment and the results were expressed as the mean % 1 standard error of the mean (SEM). Statistical analysis was performed with the statistical package Statview (Brainpower Inc. Calabasas, CA) run on a Macintosh LC11 personal computer (Apple Computer Inc, Cupertino, CA). The Student t-test for paired data (two- 
RESULTS
Effect of genistein on CML and nonnaf progenitors. As shown in Fig IA, when CML (n = 5) MNC-AC-were exposed throughout the entire culture period to genistein, a statistically significant (CFU-Mix: P s .01 at 5 pmolk; BFU-E: P 5 .01 at 5 pmol/L; CFU-GM: P c ,007 at 5 pmol/L), dose-dependent suppression of colony growth from multipotent and lineage-restricted progenitors was seen. Regression analysis showed that inhibition was linearly related (CFU-Mix: r = .84, P s .03; BFU-E: r = .88, P s .01; CFU-GM: r = .95, P 5 .003) to genistein concentration over the range tested (1 to 100 pmol/L). Similarly (Fig 1B) , continuous exposure of normal (n = 4) MNC-AC-to genistein induced a statistically significant (CFU-Mix: P s .02 at 5 pmol/L; BFU-E: P 5 .004 at 5 pmol/L; CFU-GM: P 5 .007 at 5 pmoVL), dose-dependent suppression of colony formation, with an inhibitory pattern that was linearly related (CFU-Mix: r = .79, P s .05; BFU-E: r = .85, P 5 .03; CFU-GM: r = .86, P c .02) to genistein concentrations. Genistein doses causing 50% inhibition of CML and normal progenitors were not significantly different for CFU-Mix (27 pmol/L U 23 pmoVL), BFU-E (31 pmol/L U 29 pmol/L), and CFU-GM (40 pmolfL U 32 pmolfL). Individual marrow samples exhibited variable sensitivity to the inhibitory effects of genistein, but no one failed to respond to this agent. The degree of colony suppression was not related to colony number in control cultures.
As shown in Fig 2, transient exposures (l to 18 hours) of CML (n = 5 ) and normal (n = 5) marrow to genistein (200 pmol/L) followed by washing showed a time-dependent suppression of CFU-Mix, BFU-E, and CFU-GM growth, suggesting that the effect of the drug does involve toxicity. Under the experimental conditions used in this study, no differential toxic effect was evident between CML and normal progenitors.
To investigate the effect of genistein on primitive progenitors, LTC-IC growth was also evaluated. As shown in Fig  2A, the percentages of CML-derived (n = 5 ) LTC-IC surviving after a transient exposure to genistein (200 p m o w ) for 1 (91% 2 9%), 2 (88% 2 6%), and 18 (32% t 3%) hours were significantly higher ( P 5 .05) than those of CMLderived CFU-Mix, BFU-E, and CFU-GM. Similarly, normal LTC-IC were suppressed to a significantly lower degree than were normal CFU-Mix, BFU-E, and CFU-GM (Fig 2B) . Again, no difference in the inhibitory pattern was detected by comparing CML and normal LTC-IC.
BCRLABL mRNA expression on single colonies. The quantitatively similar inhibition of CML and normal progenitors argues for an antiproliferative effect of genistein that is not specifically related to BCWABL inhibition. Several pieces of evidence suggest that BCWABL' and BCFUABLprogenitors coexisting in CML marrow have different bio- logic c h a r a c t e r i~t i c s .~~~~~ Therefore, we hypothesized that genistein could affect CML colony formation not only quantitatively, but also qualitatively. To test this hypothesis, CML colonies were individually harvested and analyzed by RT-PCR for the expression of hybrid BCFUABL mRNA. At the For personal use only. on October 23, 2017. by guest www.bloodjournal.org From
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time of the study, all of the patients but 1 were 100% Ph+ by standard cytogenetics (Table 1) . Table 2 shows that, as compared with control cultures, continuous exposure to genistein (10 to 50 pmoVL) signifi- cantly reduced the mean -t SD percentage of BCR/ABL+ progenitors (76% ? 18% U 24% ? 12%, P c .004). Figure  3 shows PCR analysis of single CFU-GM from patient no. 5 grown in the absence or continuous presence of genistein. This treatment reduced the percentage of BCR/ABL+ progenitors from 65% to 10%. As shown in Table 3 , preincubation of marrow cells with genistein resulted in a significant reduction of progenitors expressing BCWABL mRNA (75% -t 16% U 21% -t IO%, P 5 ,002).
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The capability of genistein to reduce the percentage of leukemic progenitors was also evaluated at the level of the primitive LTC-IC. In 2 of 5 cases (no. 4 and 5), molecular analysis of CFU-GM produced by LTC-IC showed a high percentage of BCWABL-progenitors; therefore, the effect of genistein could be evaluated only in 3 cases (no. 3, 6, and 7). As shown in Table 4 , in these patients, genistein treatment resulted in a marked reduction of BCWABL' LTC-IC (87% 2 12% U 37% -t 12%, P 5 .003). PCR analysis of individual CFU-GM present in marrow from patient no. 3 and produced by LTC-IC after 5 weeks in long-term culture is shown in Fig 4. In this case, genistein treatment could reduce BCWABL' LTC-IC from 80% to 35%.
To rule out the possibility that genistein could affect BCW ABL transcription, thus inducing the growth of Ph+ progenitors with nonfunctional BCWABL gene (BCWABL-), in two separate experiments colonies were individually harvested and split into two aliquots, one for cytogenetics and the other for RT-PCR. In control cultures, only 1 of 70 Ph+ colonies (1.4%) did not transcribe the BCWABL gene ( Table  5 ). In genistein-treated cultures, 13 of 60 colonies were found to be Ph+ and 12 of 13 (92%) transcribed the BCWABL gene ( Table 5 ). These findings confirm that genistein-induced increase in the percentage of nonleukemic progenitors is not related to suppression of BCWABL trascription.
Nuclear DNA fragmentation. To examine whether apoptosis is the mechanism responsible for genistein-induced inhibition of progenitor cell growth, CML-derived MNC-AC-were treated with genistein (200 pmoVL for 18 hours) and analyzed for the presence of intracellular DNA fragmentation using TdT assay. A significant portion of genistein-treated cells (38% ? 11% of the live gated population) was found to be in a progressive stage of apoptosis, whereas virtually no apoptotic cells were detected in the control samples (3% ? 2%). In addition, genistein-treated samples showed evidence of DNA fragmentation by DNA gel elec- trophoresis. To evaluate progenitor cell-enriched populations, CD34' cells were also analyzed. In Fig 5 , a representative experiment demonstrating that CD34' are induced to apoptosis on genistein treatment is shown.
DISCUSSION
Several clinical and experimental studies have shown the coexistence of normal and leukemic progenitors in
In vitro studies suggested that incubation of CML marrow cells with mafosfamide or interferon-y reduces Ph' progenitors while sparing some Ph-progenitors.?'.'' On average, cytogenetic analysis of MNC-or CML.!7.?.3-15.27.?9 CD34"derived progenitors results in percentages of Phprogenitors ranging from 20% to 40%, with 60% of CML patients being responsive to such in vitro The Vancouver experience with long-term bone marrow culture shows about SO% of CML patients having 100% Ph-LTC-IC.".'" Analysis of CD34'HLA-DR-progenitors showed the possibility of selecting a population of exclusively nonclonal hematopoietic stem cells in a substantial proportion of CML patient^.".'^ PTKs play a crucial role in regulating hematopoietic cell proliferation. The increasing knowledge of transmembrane and intracellular signal transduction phenomena now allows us to manipulate cell growth by altering signaling pathways.3" Because PTKs participate in the establishment and progression of several malignant diseases, inhibitors of PTKs represent attractive antiproliferative agents3' Genistein inhibits tyrosine phosphorylation events both at the membrane level and, distal to membrane-bound growth factor recepand 11. By acting as a general inhibitor of tyrosine kinase activity. genistein could prevent the phosphorylation of regulatory proteins such as Grb-2 and Shc that have the potential to stimulate Ras and might play a crucial role in the pathogenesis of CML.7.X."-13
In the present study, we show that genistein strongly inhibits marrow-derived CML as well as normal CFU-Mix, BFU-E, and CFU-GM, while sparing a substantial proportion of LTC-IC. Under the experimental conditions used in this study, both continuous and transient exposure of marrow cells to genistein induced a similar antiproliferative effect on leukemic and normal progenitors. This argues for a nontorS,3?-34. 48 Induces .
apoptosis and inhibits topoisomerases I Values represent the number of Ph' or PCR' colonies/number of colonies tested. specific inhibitory effect occumng through a complete shutoff of the FTK signaling pathways rather than a selective inhibition of BCWABL tyrosine kinase, as has been shown for other PTK inhibitor^.^^.^" Analysis of MNC-AC-and CD34' cells for intracellular DNA fragmentation using DNA gel electrophoresis and TdT assay showed that apoptosis mediates genistein-induced inhibition of progenitor cell growth.
Because BCWABL' and BCWABL-progenitors coexisting within the same CML marrow have different biologic characteristi~s.~~.'~ it was hypothesized that genistein could affect the growth of leukemic progenitors not only quantitatively, but also qualitatively. Analysis of individual colonies for the expression of hybrid BCWABL mRNA showed that genistein-induced growth inhibition was associated with suppression of leukemic CFU-GM and LTC-IC and the reemergence of nonclonal progenitors. Colonies plucked for RT-PCR analysis were compact and contained 2200 cells. A transient exposure to genistein failed to affect the morphology or the size of colonies detected in methylcellulose culture or produced by LTC-IC after 5 weeks in long-term culture (data not shown). Overall, genistein induced a significant increase in the percentage of BCWABL-primitive and committed progenitors (Tables 2 through 4) . although a complete disappearance of leukemic progenitors was never detected.
Molecular data are not in contrast with the equal sensitivity of CML and normal progenitors to the growth inhibitory effect of genistein. In fact, normal progenitors persisting in CML patients are biologically and kinetically different from progenitors detectable within normal narrow.^'.^^ We hypothesize that, due to their intrinsic biologic properties, residual BCWABL-progenitors within CML marrow are capable to escape the inhibitory action of genistein and have the possibility to re-express their proliferative potential. As shown by DNA fragmentation, genistein may favor the reemergence of nonclonal progenitors by triggering apoptosis of leukemic progenitors. However, the capacity of genistein to preferentially induce apoptosis of leukemic progenitors while sparing the nonleukemic ones remains to be investigated.
In agreement with data from the Vancouver group," we detected a concentration of LTC-IC in CML marrow that was decreased on average to less than 10% of the LTC-IC concentration in normal marrow. To get adequate numbers of colonies from genistein-treated samples, LTC-IC were assayed by setting up three separate cultures on day 0. This allowed us to analyze BCWABL expression in an average number of 20 (range, 16 to 30) genistein-treated CFU-GM produced by LTC-IC after 5 weeks in LTC ( Table 4) . Similar numbers of colonies produced by committed CFU-GM were analyzed (Tables 2 and 3 ). According to calculations derived from a binomial distribution:' analysis of 20 colonies excludes 14% BCWABL' colonies with a probability of 0.05% (assuming all colonies analyzed prove to be BCWABL-). Based on these calculations as well as the constant evidence of mosaicism in our samples, analysis of an average number of 20 colonies allows a statistically significant detection of BCWABL-progenitors within each population (control or genistein-treated).
The capability to select for BCWABL-progenitors is not a general property of antiproliferative agents with therapeutic relevance in the treatment of CML. Interferon-a has been shown to inhibit to a similar extent CML and normal progenitors and has been shown to lack any property to select for BCWABL-progenitor^.'^ The percentage reduction of progenitors expressing the hybrid BCWABL mRNA is not caused by a suppression of BCWABL transcription, as has been described for interferon-a.'? In fact, analysis of individual colonies both by cytogenetics and RT-PCR showed similar percentages of Ph-and BCWABL-colonies generated from genisteintreated samples, thus excluding that genistein acts by suppressing BCWABL transcription. This is further supported by the evidence of Kaur et al,s4 who have shown that preincubation of K562 cells with the tyrphostin AG957 inhibits cell growth, ~2 1 0~" "~' tyrosine kinase activity, and DNA synthesis as early as 2 hours, a time at which RNA and protein synthesis were not affected.
For
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The use of PTK inhibitors for marrow purging has been p r o p o~e d .~~~~~~~~
The in vitro selection for normal hematopoietic stem and progenitor cells from within CML marrow and the potential for using these cells as leukemia-free autografts has been the topic of increasing d i s c~s s i o n . " *~~~~~~~"~~ Data reported herein show the possibility of selecting nonclonal LTC-IC as well as CFU-GM from CML marrow by means of a simple incubation with the PTK inhibitor genistein, thus suggesting that it may be feasible to select a population of benign progenitors from CML marrow that could be used for autografting patients without suitable allogeneic bone marrow donors. As compared with maf~sfamide,'~ genistein appears to exert a stronger antileukemic effect, thus allowing us to predict a better clinical efficicacy in the context of marrow purging. The toxicity of genistein to normal marrow progenitors could prevent its in vivo use for autografting purposes. However, other drugs, such as the cyclophosphamide derivative mafosfamide, which is at least as toxic as genistein to normal marrow progenitors but, similarly to genistein, spares LTC-IC,29 have been extensively used in vivo for autografting without evidence of clinically unacceptable damage of hematopoietic f u n c t i~n .~~. '~ An additional problem related to the in vivo use of genistein is represented by lot-to-lot changes in the biologic activity of the molecule. In this respect, the recently described use of synthetic PTK inhibitors may represent an important alternati~e.'~ The availability of several natural and synthetic PTK inhibitors will allow to screen for compounds with a more effective antileukemic action. Further investigations are required to explore the therapeutic potential of PTK inhibitors alone o r in combination with other agents, including biologic response modifiers and antisense oligonucleotides, as well as their effects on highly purified hematopoietic cell subpopulations to improve selection of benign progenitors in CML.
